Valneva SE Logo

Valneva SE

Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.

VLA | PA

Overview

Corporate Details

ISIN(s):
AT0000A10B99 (+3 more)
LEI:
969500DIVIP5VKNW4948
Country:
France
Address:
6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company leverages its expertise to manage a portfolio of commercialized vaccines, including a single-shot vaccine for chikungunya, and to advance a clinical pipeline of candidates. Key development programs target diseases such as Lyme disease, Shigella, and Zika.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-09 15:59
Major Shareholding Notification
Franchissement de seuil
French 205.6 KB
2025-10-06 17:35
Capital/Financing Update
Valneva consolide sa position de trésorerie en refinançant sa dette auprès de P…
French 202.1 KB
2025-10-06 17:35
Capital/Financing Update
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advis…
English 212.7 KB
2025-08-07 07:17
Regulatory News Service
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du v…
French 218.7 KB
2025-08-07 07:17
Regulatory News Service
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccin…
English 222.5 KB
2025-07-11 17:35
Regulatory News Service
Valneva annonce la levée de la restriction temporaire de l'Agence européenne de…
French 165.8 KB
2025-07-11 17:35
Regulatory News Service
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction …
English 208.0 KB
2025-06-25 17:45
Post-Annual General Meeting Information
Valneva annonce l’approbation des résolutions présentées à son Assemblée Généra…
French 145.4 KB
2025-06-25 17:45
Post-Annual General Meeting Information
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY…
English 119.4 KB
2025-06-05 17:45
Earnings Release
Valneva annonce des résultats positifs de Phase 2 à six mois sur la persistance…
French 236.5 KB
2025-06-05 17:45
Earnings Release
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Resu…
English 178.3 KB
2025-06-05 07:30
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Déclaration d’actions et de droits de vote - mai 2025
French 160.2 KB
2025-06-05 07:30
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Declaration of shares and voting rights - May 2025
English 170.0 KB
2025-06-04 07:00
Pre-Annual General Meeting Information
Valneva annonce la mise à disposition des documents préparatoires à son Assembl…
French 115.0 KB
2025-06-04 07:00
Pre-Annual General Meeting Information
Valneva Announces Availability of Documentation for its Combined Shareholder Me…
English 122.8 KB

Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Valneva SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-03-18 N/A Other Buy 44,222 N/A
2024-01-03 N/A Other Other 34,802 N/A
2023-06-20 N/A Other Sell 192,547 1,406,228.50 EUR
2023-06-19 N/A Other Sell 30,661 209,629.26 EUR
2023-06-16 N/A Other Sell 85,589 582,493.06 EUR
2023-06-15 N/A Other Sell 28,179 189,503.78 EUR
2023-06-14 N/A Other Sell 228,951 1,519,914.11 EUR
2023-06-13 N/A Other Sell 29,401 187,922.37 EUR
2023-06-12 N/A Other Sell 117,854 733,782.57 EUR
2023-05-10 N/A Other Buy 87,523 N/A

Peer Companies

Company Country Ticker View
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden IBT
Intercure Ltd. Logo
Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.
Israel INCR
Intervacc AB Logo
Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.
Sweden IVACC
iNtRON Biotechnology, Inc. Logo
Develops phage therapeutics and molecular diagnostics to combat infectious diseases.
South Korea 048530
Inventage Lab Inc. Logo
Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.
South Korea 389470
Ipsen Logo
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
France IPN
IRLAB Therapeutics Logo
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden IRLAB
ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea 086890
IVF HARTMANN Holding AG Logo
Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.
Switzerland VBSN
Japan Tissue Engineering Co., Ltd. Logo
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan 7774

Talk to a Data Expert

Have a question? We'll get back to you promptly.